Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvalYear |
1998
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J06BB16
|
| gptkbp:brand |
gptkb:Synagis
|
| gptkbp:CASNumber |
gptkb:188039-54-5
|
| gptkbp:cost |
expensive
|
| gptkbp:developedBy |
gptkb:MedImmune
|
| gptkbp:halfLife |
20 days
|
| gptkbp:hasMolecularFormula |
C6418H9910N1694O1987S46
|
| gptkbp:indication |
high-risk infants
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to RSV F protein and inhibits viral entry
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:product |
IgG1 kappa monoclonal antibody
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
injection site reaction rash |
| gptkbp:target |
gptkb:RSV_F_protein
|
| gptkbp:UNII |
P0MUJ6XSE6
|
| gptkbp:usedFor |
prevention of respiratory syncytial virus infection
|
| gptkbp:WHOModelListOfEssentialMedicines |
no
|
| gptkbp:bfsParent |
gptkb:respiratory_syncytial_virus
gptkb:RSV |
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
palivizumab
|